Expand TNXP Menu
TNXP MENU

TNXP Latest Press Releases

-- March 31, 2026 --

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 Globe Newswire 7:00 AM

-- March 26, 2026 --

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain Globe Newswire 7:00 AM

-- March 23, 2026 --

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 Globe Newswire 4:32 PM

-- March 18, 2026 --

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 Globe Newswire 4:58 PM

-- March 17, 2026 --

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 4:35 PM

-- March 13, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing Globe Newswire 8:35 AM

-- March 12, 2026 --

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Globe Newswire 5:30 PM

-- March 10, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th Globe Newswire 10:21 AM
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia Globe Newswire 8:00 AM

-- March 9, 2026 --

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting Globe Newswire 4:30 PM

-- March 5, 2026 --

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development Globe Newswire 4:15 PM

-- March 3, 2026 --

Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting Globe Newswire 4:30 PM
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market Globe Newswire 6:00 AM

-- February 25, 2026 --

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March Globe Newswire 7:00 AM

-- January 30, 2026 --

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit Globe Newswire 7:00 AM

-- January 6, 2026 --

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 Globe Newswire 7:00 AM

-- December 29, 2025 --

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering Globe Newswire 7:57 AM
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Globe Newswire 7:45 AM

-- December 16, 2025 --

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University Globe Newswire 7:00 AM

-- December 9, 2025 --

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Globe Newswire 7:00 AM

-- December 4, 2025 --

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations Globe Newswire 8:30 AM

-- November 24, 2025 --

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder Globe Newswire 7:00 AM

-- November 17, 2025 --

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes